Background Ischaemia-modified albumin (IMA) is being studied as a new marker for reversible ischaemia in patients presenting with possible cardiac chest pain. The conditions under which samples are stored prior to analysis may be critical in influencing the analytical result and hence the cut-off used in any particular study.
Introduction
The ischaemia-modi¢ed albumin (IMAt) test is based on the modi¢cation of the N-terminal amino-acid residues of serum albumin by some facet of ischaemia such that the binding of divalent metal ions, particularly cobalt and nickel, is altered. 1 The degree of alteration can be quantitated by adding a ¢xed amount of cobalt to serum and then measuring the unbound cobalt colorimetrically: this is the basis of the IMA test. 2 The test is coming under increasing critical review. 3--9 Ischaemia that may not be su⁄cient to cause cell necrosis increases IMA which has been shown to be a sensitive marker for myocardial ischaemia. 8 As it detects ischaemic changes early (within 3 h of occurrence), it has been suggested that IMA would provide a suitable early marker in a rule-out chest pain protocol. 10 According to the manufacturer's recommendations, the test has a shelf-life of just two weeks, and even when fully utilized within this time frame results in a cost of about »15 per sample. For this reason, and also to analyse stored samples retrospectively from other studies, a number of reports describe the analysis of samples stored at temperatures of À201C or lower. 3, 4, 8, 11 To be able to extrapolate ¢ndings from studies on frozen samples to those undertaken with realtime analysis, it is important to con¢rm that freezing and storage have no e¡ect on the result.
The literature to date contains a number of reports ranging from no e¡ect of storage at À201C to those describing a signi¢cant change if careful conditions during thawing are not maintained. 3, 4, 8, 11 Studies on storage have usually been performed on relatively few samples. The company that markets the test (formerly Ischemia Technologies, now Inverness Medical) recommends that storage at À201C is satisfactory.
We have recently completed the Presentation IMA in the Emergency Department (PRIMA) study, designed to assess the suitability of IMA as a risk strati¢cation marker in patients presenting with possible cardiac chest pain. 12 As part of this, we were able to analyse 68 specimens both in realtime (unfrozen) and after storage at À201C, and we now report our results.
Methods
Samples for IMA originating from the ¢rst 68 patients recruited at Bristol into the PRIMA study were analysed both in the immediate period following collection and after storage at À201C. The time of collection was documented for all samples. After centrifugation of the serum separator tube, approximately 1mL of serum was stored in a 1.5 mL polypropylene screwcapped tube at À201C. Analysis for IMA then took place for the unfrozen serum. Periodically, a small batch of frozen samples was thawed for 30 min at room temperature while mixing and then promptly analysed. All samples were analysed within 2.5 h of collection, excluding time spent at À201C. The duration of time spent frozen ranged from 24 h to18 days (mean 5 days).
IMA analyses were performed on a Beckman LX20 analyser using the albumin cobalt binding test (Ischemia Technologies, Inc, Colorado, USA; now provided by Stirling Medical Innovations, Stirling, UK) set up according to the manufacturer's instructions and accredited for IMA analysis after a test run of the manufacturer's reference panel of samples. Manufacturer's information indicates a detection limit of 18 units, an upper limit of the measuring range of 173 units, an inter-assay coe⁄cient of variation (CV) of 6.6% at 87 units and a decision value of 85 units.
To avoid the possible confounding e¡ect that may arise when a large group of samples is analysed on a single occasion that coincides with an allowable but distinct shift in the assay, the frozen samples were analysed on 20 occasions in batch sizes from one to seven. Internal quality control values were recorded for the days when the realtime and frozen duplicates were analysed.
Results
The mean (range) of the IMA realtime analyses was 87.5 units (46--108) and that of the frozen samples was 90.5 (41--114), t ¼ À5.19, Po0.00001 (paired t-test). A Bland--Altman plot indicates that the di¡erence was not concentration dependent ( Figure 1 ). During the period of analysis (13.01.04--20.08.04), the mean (SD)(CV)(n) for a manufacturer's control value near the decision cut-o¡ of 85 was 82.9 (2.9)(3.5)(134). In particular, the mean value for this control for the days on which the realtime IMA analyses were performed was 83.3 (n ¼ 67), and for the days on which analysis was done on the frozen samples was 82.2 (n ¼ 20), indicating no systematic positive bias that could account for the increased values in the frozen samples. One sample that was lipaemic yielded a value of 41 units.
Discussion
These results indicate a small but highly statistically signi¢cant increase in IMA upon storage at À201C and subsequent analysis under the conditions described. These changes occur irrespective of concentration and thus have important implications for the choice of decision point used in clinical studies. The number of specimens analysed is much greater than in any previously reported study. While the numerical value of this increase is small in percentage terms, and well within the imprecision of the assay such that it might not be noticed in everyday use, it highlights the variability of results obtained when stability of samples has been examined.
Previous work reports no signi¢cant di¡erence between ¢ve samples analysed soon after collection and after a period at À201C; 4 that samples frozen at À201C or colder within 96 h of collection showed no signi¢cant loss of recovery after thawing and recentrifugation before analysis; 3 that samples (number undisclosed) stored at À201C or colder and gently vortexed after thawing showed no signi¢cant di¡erence in results from fresh specimens; 8 and that for 10 samples, after storage at À201C, the variation in IMA ranged from À2.7 to þ 4.7% of fresh values provided that the frozen tubes were thawed at 41C for 20 min. 11 When the tubes were thawed at room temperature for 20 min, values increased by 15% on average. 11 Studies on stability at a range of temperatures above freezing have found stability in serum for 6 h at ambient temperature and 12 h at 41C; 13 a signi¢cant increase after 4 h irrespective of temperature 14 and stability for 5 h at 41C in a closed tube under vacuum that was centrifuged once clotting occurred. 11 In samples left to clot at room temperature and then centrifuged just prior to analysis at 8 h, there was a 10% decrease in values. 11 In some clinical studies, samples were stored for up to two weeks at 41C prior to analysis. 2, 3 Clearly, there are small but signi¢cant changes in IMA value dependent upon the conditions of specimen storage prior to analysis, whether in realtime or after freezing. These conditions should be described as fully as possible for any study, a condition not met by all. The use of a single cut-o¡ does not seem appropriate and must be decided by receiver operating characteristic curves for each study, again a prerequisite not met by some.
It has been reported that triglycerides do not interfere with the assays. 11 In this study and in the main PRIMA study from which these samples were drawn, very low values (o60) were associated with lipaemia and this e¡ect needs to be investigated further.
Conclusion
We have demonstrated a small but signi¢cant increase in IMA results in samples stored at À201C compared with those analysed within 2.5 h of collection. The literature describes a range of stability e¡ects when IMA samples are analysed with or without freezing. Conditions of storage should be de¢ned for all clinical studies.
